For FLT3-TKD-mutated AML in younger, fit adults, the RATIFY study showed that this group benefitted from the addition of midostaurin; however, it is unclear whether this applies in the context of lower-intensity venetoclax-based regimens in older adults. The gene discussed is FLT3; the disease is acute myeloid leukemia.